Patent Application
Utility
App. No. 18/587,790
· Confirmation No. 1632
PTPN11 INHIBITORS
Applicant:
NAVIRE PHARMA, INC.
Abandoned -- Incomplete Application (Pre-examination)
|
⬇ PDF
|
Code | Description | Pages | ||
|---|---|---|---|---|---|
| 2024-11-14 | ABN |
Abandonment | 2 | View | |
| 2024-09-23 | N417.PYMT |
Electronic Fee Payment | 2 | View | |
| 2024-09-23 | PEFR |
Applicant Response to Pre-Exam Formalities Notice | 2 | View | |
| 2024-09-23 | N417 |
Electronic Filing System Acknowledgment Receipt | 2 | View | |
| 2024-09-16 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2024-09-16 | NT.INC.REPLY |
Notice of Incomplete Reply | 3 | View | |
| 2024-08-09 | N417.PYMT |
Electronic Fee Payment | 2 | View | |
| 2024-08-09 | N417 |
Electronic Filing System Acknowledgment Receipt | 2 | View | |
| 2024-03-12 | APP.FILE.REC |
Filing Receipt | 4 | View | |
| 2024-03-12 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2024-03-12 | NTC.MISS.PRT |
Notice to File Missing Parts | 3 | View | |
| 2024-03-12 | WELCOME.LET |
Welcome Letter from USPTO Director and Deputy Director | 1 | View | |
| 2024-02-26 | SPEC |
Specification | — | View | |
| 2024-02-26 | SPEC |
Specification | 120 | View | |
| 2024-02-26 | CLM |
Claims | 14 | View | |
| 2024-02-26 | ABST |
Abstract | 1 | View | |
| 2024-02-26 | DRW |
Drawings-only black and white line drawings | 2 | View | |
| 2024-02-26 | N417 |
Electronic Filing System Acknowledgment Receipt | 3 | View | |
| 2024-02-26 | TRNA |
Transmittal of New Application | 1 | View | |
| 2024-02-26 | ADS |
Application Data Sheet | 10 | View | |
| 2024-02-26 | OATH |
Oath or Declaration filed | 5 | View |
Inventors
Philip JONES
Houston, TX
Barbara CZAKO
Bellaire, TX
Christopher L. CARROLL
Houston, TX
Pijus MANDAL
Sugarland, TX
Jason CROSS
Pearland, TX
Attorneys & Agents of Record
Prosecution
- Customer No.
- 188639
- Docket No.
- 052736-504C02US
- Confirmation No.
- 1632
Parent
is a Continuation of
→
App. 17/380,943
· US 11,945,815
Filed 2021-07-20
· Patented Case
Parent
is a Continuation of
→
App. 16/536,923
· US 11,104,675
Filed 2019-08-09
· Patented Case
Parent
Claims priority from a provisional application
→
App. 62/773,921
Filed 2018-11-30
· Provisional Application Expired
Parent
Claims priority from a provisional application
→
App. 62/717,588
Filed 2018-08-10
· Provisional Application Expired
Child
is a Continuation of
→
App. 18/799,303
Filed 2024-08-09
· Docketed New Case - Ready for Examination
BRIDGEBIO PHARMA, INC.,
QED THERAPEUTICS, INC.,
EIDOS THERAPEUTICS, INC.,
ML BIO SOLUTIONS INC.,
NAVIRE PHARMA, INC.,
CANTERO THERAPEUTICS, INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
FERRO THERAPEUTICS, INC.,
BRIDGEBIO SERVICES INC.
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL
Recorded 2025-03-05
from
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
BRIDGEBIO PHARMA, INC.,
BRIDGEBIO SERVICES INC.,
CANTERO THERAPEUTICS, INC.,
EIDOS THERAPEUTICS, INC.,
FERRO THERAPUETICS, INC.,
ML BIO SOLUTIONS INC.,
NAVIRE PHARMA, INC.,
QED THERAPEUTICS, INC.
SECURITY INTEREST
Recorded 2024-06-28
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
- App. No.
- 18/587,790
- Filed
- 2024-02-26
External Links